@article{5a691a307e294e7bbf7c59ea3333d004,
title = "Gender stratified adjustment of the DAS28-CRP improves inter-score agreement with the DAS28-ESR in rheumatoid arthritis",
keywords = "Age, Biologics, BMI, BSRBR, CRP, DAS, DAS28, ESR, Gender, RA",
author = "\{BSRBR-RA Contributors Group\} and Hamann, \{Philip D.H.\} and Gavin Shaddick and Kimme Hyrich and Amelia Green and Neil McHugh and Pauling, \{John D.\}",
note = "Funding Information: The authors acknowledge the enthusiastic collaboration of all consultant rheumatologists and their specialist nurses in the UK in providing the data (visit www.bsrbr. org for a full list of contributors). The authors would like to gratefully acknowledge the support of the National Institute for Health Research, through the Comprehensive Local Research Networks at participating centres. In addition, the authors acknowledge support from the BSR Executive, the members of the BSRBR Registers Committee and the BSRBR Project Team in London for their active role in enabling the register to undertake its tasks. The authors also acknowledge the seminal role of the BSR Clinical Affairs Committee for establishing national biologic guidelines and recommendations for such a register. Finally, the authors would like to acknowledge the Arthritis Research UK Centre for Epidemiology, which provided the infrastructure support for the study. P.D.H.H{\textquoteright}s research was funded by the BSR through the Clinical Research Fellowship in Musculoskeletal Epidemiology. This work was conducted on behalf of BSR and P.D.H.H. would like to thank BSR for its help and support. Funding Information: Funding: This work was supported by the British Society for Rheumatology (BSR). The BSR commissioned the BSR Biologics Register in RA (BSRBR-RA) as a UK wide national project to investigate the safety of biologic agents in routine medical practice. K.H. is the principal investigator. BSR receives restricted income from UK pharmaceutical companies, including Abbvie, Celltrion, Hospira, MSD, Pfizer, SOBI, Samsung, UCB and Roche. This income finances a wholly separate contract between the BSR and the University of Manchester. The principal investigator and the BSRBR-RA team at the University of Manchester have full academic freedom and are able to work independently of pharmaceutical industry influence. All decisions concerning analyses, interpretation and publication are made autonomously of any industrial contribution. Members of the BSRBR-RA University of Manchester team, BSR trustees, committee members and staff complete an annual declaration in relation to conflicts of interest. All relevant information regarding serious adverse events outlined in the manuscript have been reported to Publisher Copyright: {\textcopyright} The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology.",
year = "2019",
month = may,
doi = "10.1093/rheumatology/key374",
language = "English",
volume = "58",
pages = "831--835",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "5",
}